Interestingly, Subtype 3 emerged as an outlier with an atypical A+/T− CSF biomarker profile, characterized by low tau levels despite elevated neurofilament, enrichment in African Americans and men, and distinct proteomic signatures that challenge conventional AD diagnostic classification. This evidence concerns the gene MAPT and Alzheimer disease.